Back to top

Vaccines and Therapeutics

Current vectors for the delivery of vaccines and biological therapeutics exhibit a number of issues including low loading capacity, poor transfection properties, poor preclinical tolerability, and unwanted immune responses.

N4 Pharma develops novel silica nanoparticle delivery systems with unique structures designed as superior alternatives to lipid systems and viral-like delivery vectors. It is undertaking pre-clinical research of these technologies to demonstrate the capabilities of these technologies. N4 will then license the technology to commercial partners for improved delivery of their own products.